Clinical Trials Logo

de Novo clinical trials

View clinical trials related to de Novo.

Filter by:
  • None
  • Page 1

NCT ID: NCT04687761 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Start date: November 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I-II trial based on the combination of three drugs regimen LDAC or Azacitidine + Venetoclax + Quizartinib that in this population could be well tolerated by a sequential type administration. The first objective is to achieve rapid control of the disease, using two different schemes, one based in Azacitidine and the other in LDAC, by dose escalation in phase I of the trial. The second goal is to prevent relapse through a maintenance schedule. Phase II will study the efficacy and safety of the recommended dose for Phase II

NCT ID: NCT03600948 Terminated - Clinical trials for Restenoses, Coronary

BIOFLOW-SV All Comers Registry

BIOFLOW-SV
Start date: August 27, 2018
Phase:
Study type: Observational

Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.

NCT ID: NCT02067143 Completed - Secondary Clinical Trials

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

LAL1913
Start date: May 20, 2014
Phase: Phase 2
Study type: Interventional

This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the achievement of an early negative minimal residual disease (MRD) status. The MRD study supports a risk/MRD-oriented final consolidation phase.